Aaron Brinkworth

Mr Brinkworth had a 22-year career with Gilead Sciences, Inc. (Nasdaq: GILD) (Gilead) during which time the company grew from a small biotech-pharma company to a multi-billion-dollar global company with annual sales of over USD $27 billion. He held several commercial, licensing, and patient access roles at Gilead, including that of Executive Director - Global Patient Solutions, where he was responsible for commercial and access strategies for emerging markets. He led Gilead's commercial and access operations in the Asia Pacific (APAC) where he managed a geographically dispersed team and partners across 31 APAC countries. He also serves on a NFP Board for The Royal Lifesaving Society of Western Australia and is a NED on the boards of Lixa Pty Ltd, a biotech company focused on antimicrobial resistance.